Third Class Of Drugs Should Not Be “Completely Closed Down” – Ganley
This article was originally published in The Tan Sheet
Executive Summary
Debate on the merits of a third class of drugs could resurface as FDA considers Rx-to-OTC switch applications of drugs indicated for chronic conditions
You may also be interested in...
FDA Plans Behind-The-Counter Drugs Meeting, Mulls “Transitional” Status
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders
FDA Plans Behind-The-Counter Drugs Meeting, Mulls “Transitional” Status
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders
FDA Plans Behind-The-Counter Drugs Meeting, Mulls “Transitional” Status
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders